Get started
Author

Bérengère Génin

ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease
2004 · Sandrine Macé, Emmanuelle Cousin, et al. · Neurobiology of Disease · 110
Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients
2017 · Florence Koeppel, Steven Blanchard, et al. · PLoS ONE · 108
PDF
Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2014 · Gilles Manceau, Sandrine Imbeaud, et al. · Clinical Cancer Research · 103
Does epilepsy in multiplex autism pedigrees define a different subgroup in terms of clinical characteristics and genetic risk?
2013 · Claire Amiet, Isabelle Gourfinkel-An, et al. · Molecular Autism · 52
PDF
Epilepsy in Simplex Autism Pedigrees is Much Lower Than the Rate in Multiplex Autism Pedigrees
2013 · Claire Amiet, Isabelle Gourfinkel-An, et al. · Biological Psychiatry · 22
A scoring strategy combining statistics and functional genomics supports a possible role for common polygenic variation in autism
2014 · Jérôme Carayol, Gerard D. Schellenberg, et al. · Frontiers in Genetics · 12
PDF
Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA
2024 · Grégoire Marret, Constance Lamy, et al. · Oral Oncology · 11
Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC phase III trial.
2014 · Pierre Laurent-Puig, John A. Bridgewater, et al. · Journal of Clinical Oncology · 3
Mir-31-3P is a Predictive Biomarker of Cetuximab Effects in a Post-Hoc Analysis in the New Epoc Study
2014 · P. Laurent-Puig, J.A. Bridgewater, et al. · Annals of Oncology · 1
Abstract 3363: Spatial and longitudinal tumor heterogeneity in head and neck squamous cell carcinoma patients treated with primary surgery
2023 · Grégoire Marret, Constance Lamy, et al. · Cancer Research
Supplementary Materials and Methods, Figure Legends, Tables 1 - 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
Supplementary Figure 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
PDF
Supplementary Figure 4 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
Supplementary Figure 2 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
PDF
Supplementary Figure 1 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
Supplementary Figure 5 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
PDF
Data from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
Data from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
Supplementary Figure 1 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
PDF
Supplementary Figure 5 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
Supplementary Materials and Methods, Figure Legends, Tables 1 - 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
PDF
Supplementary Figure 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
Supplementary Figure 2 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
Supplementary Figure 4 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023 · Gilles Manceau, Sandrine Imbeaud, et al.
PDF
Hsa-mir-31-3p effects on gene expression in colorectal cancer cell lines and patients.
2013 · Raphaële Thiébaut, Marc Vincent, et al. · Journal of Clinical Oncology
Works count: 25
Citation count: 422
H-index: 7
I10-index: 7
Year
Topic
Type